Compare Dollar Tree, Inc. (DLTR) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dollar Tree, Inc. vs Medpace Holdings Inc — how do they compare? Dollar Tree, Inc. trades at $117.45 (market cap $22.26B), while Medpace Holdings Inc trades at $617.27 (market cap $16.82B). The key difference: Dollar Tree, Inc. is the larger of the two by market cap, and Medpace Holdings Inc is trading nearer its 52-week high, Dollar Tree, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Dollar Tree, Inc. for 58 Days and Medpace Holdings Inc for 14 Days on average.
| DLTR | MEDP | |
|---|---|---|
Market Cap | $22.26B | $16.82B |
Volume | 2,317,428 | 223,093 |
Sector | Consumer Staples | Health |
52-Week High | $141.21 | $630.19 |
52-Week Low | $86.80 | $393.42 |
Typical Hold Time | 58 Days | 14 Days |
Enterprise Value | $28.87B | $16.44B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dollar Tree (DLTR) trades at $117.42, up 0.96% today, with a bullish technical signal and strong earnings beats in recent quarters. The stock shows robust profitability with a 45.87% ROE and trades at a modest P/E of 14.54. Recent news highlights strategic initiatives and store expansions supporting growth, though margin risks from tariffs and reinvestment remain a focus.
The outlook is positive with a consensus price target of $139.33, implying 18.7% upside, but investors face risks from volatile margins, high debt levels, and competitive pressures. Earnings improvement and institutional buying provide support, yet the stock's recent decline of 17.9% over the past month underscores near-term challenges.
MEDP trades at $604.25, up 0.22% today, with a neutral technical signal and strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected on October 21, 2026. Revenue grew to $2.53 billion in 2025, with a net income margin of 17.67% and robust ROE of 162.15%. Analyst consensus is a $620.44 price target, though institutional sentiment is mixed with recent CEO share sales.
Outlook remains positive given earnings momentum and projected 2026 revenue growth to $2.8 billion. Key risks include high valuation multiples and insider selling. The stock offers upside to consensus target but requires monitoring of Q3 earnings and competitive pressures in medical services.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dollar Tree, Inc.
Dollar Tree operates discount stores in the U.S. and Canada, including 8,647 shops under its namesake banner and 8,016 Family Dollar units (as of the end of fiscal 2021). The eponymous chain features branded and private-label goods, generally at a $1.25 price. Around 45% of Dollar Tree stores' fiscal 2021 sales came from consumables (including food, health and beauty, and household paper and cleaning products), nearly 50% from variety items (including toys and housewares), and just over 5% from seasonal goods. Family Dollar features branded and private-label goods at prices generally ranging from $1 to $10, with over 76% of fiscal 2021 sales from consumables, 9% from seasonal/electronic items (including prepaid phones and toys), 8% from home products, and 6% from apparel and accessories.
Read more on DLTR →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
